Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenovoRxRNXT +1.44%32 Equity-to-Asset is 0.81 as of Mar. 2026, which is 14% above its 10-year median of 0.71. GuruFocus rates RNXT with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, RenovoRx ranks better than 67.96% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. RenovoRx's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $11.27 Mil. RenovoRx's Total Assets for the quarter that ended in Mar. 2026 was $13.96 Mil.
Therefore, RenovoRx's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.81.
The historical rank and industry rank for RenovoRx's Equity-to-Asset or its related term are showing as below:
RNXT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -12.33 Med: 0.71 Max: 0.97
Current: 0.81
During the past 7 years, the highest Equity to Asset Ratio of RenovoRx was 0.97. The lowest was -12.33. And the median was 0.71.
RNXT's Equity-to-Asset is ranked better than 67.96% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs RNXT: 0.81
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
RenovoRx Equity-to-Asset Related Terms
RenovoRx Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for RenovoRx's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNXT vs APLM, HYPD, PDSB: Equity-to-Asset Comparison
For the Biotechnology subindustry, RenovoRx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RenovoRx Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RenovoRx's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where RenovoRx's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
RenovoRx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RenovoRx (RNXT) has a Equity-to-Asset of 0.81 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on RenovoRx and its competitors. This is 14% above median its historical median of 0.71. According to the industry distribution chart, RenovoRx ranks #454 out of 1417 companies in the Biotechnology industry, placing it in the top 32%.
Is RenovoRx's Equity-to-Asset too high?
RenovoRx's current Equity-to-Asset of 0.81 is 14% above median its 10-year median of 0.71. The Biotechnology industry median Equity-to-Asset is 0.68. RenovoRx's value of 0.81 is 19.1% above this industry median. Based on the distribution chart, RenovoRx ranks #454 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RenovoRx has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does RenovoRx's Equity-to-Asset compare to APLM and HYPD?
According to the Biotechnology industry distribution chart, RenovoRx ranks #454 out of 1417 companies for Equity-to-Asset. This puts RenovoRx in the upper half of its industry. The industry median Equity-to-Asset is 0.68. RenovoRx's value of 0.81 is 19.1% above this benchmark. While the company's 10-year median is 0.71 vs. the industry median of 0.68, RenovoRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RenovoRx's current Equity-to-Asset of 0.81 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on RenovoRx and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RenovoRx's current Equity-to-Asset is 0.81, which is 14% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovoRx stock overvalued right now?
RenovoRx (RNXT) has a current Equity-to-Asset of 0.81. The current Equity-to-Asset is 0.81, which is 14% above median its 10-year median of 0.71 and 19.1% above the Biotechnology industry median of 0.68. RenovoRx's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For RenovoRx (RNXT), the current Equity-to-Asset is 0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
32GF Score
Get the complete analysis for RNXT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNXT has been successfully added to your 
